Latest Insider Transactions at Hca Healthcare, Inc. (HCA)
This section provides a real-time view of insider transactions for Hca Healthcare, Inc. (HCA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of HCA Healthcare, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of HCA Healthcare, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 14
2025
|
Jennifer Berres SVP & Chief Human Res. Officer |
SELL
Open market or private sale
|
Direct |
9,533
-21.26%
|
$3,069,626
$322.63 P/Share
|
|
Feb 13
2025
|
Sammie S Mosier SVP & Chief Nurse Executive |
SELL
Payment of exercise price or tax liability
|
Direct |
227
-2.0%
|
$72,867
$321.92 P/Share
|
|
Feb 13
2025
|
Sammie S Mosier SVP & Chief Nurse Executive |
BUY
Grant, award, or other acquisition
|
Direct |
845
+6.93%
|
-
|
|
Feb 13
2025
|
Christopher F. Wyatt SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
227
-0.55%
|
$72,867
$321.92 P/Share
|
|
Feb 13
2025
|
Christopher F. Wyatt SVP & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
845
+2.01%
|
-
|
|
Feb 13
2025
|
Samuel N Hazen CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,742
-6.21%
|
$1,522,182
$321.92 P/Share
|
|
Feb 13
2025
|
Samuel N Hazen CEO |
BUY
Grant, award, or other acquisition
|
Direct |
13,218
+14.75%
|
-
|
|
Feb 13
2025
|
Mike A Marks EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
172
-26.96%
|
$55,212
$321.92 P/Share
|
|
Feb 13
2025
|
Mike A Marks EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
638
+50.0%
|
-
|
|
Feb 13
2025
|
Michael R Mc Alevey EVP & Chief Legal & Admin Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
531
-16.45%
|
$170,451
$321.92 P/Share
|
|
Feb 13
2025
|
Michael R Mc Alevey EVP & Chief Legal & Admin Off. |
BUY
Grant, award, or other acquisition
|
Direct |
2,117
+39.61%
|
-
|
|
Feb 13
2025
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
583
-1.82%
|
$187,143
$321.92 P/Share
|
|
Feb 13
2025
|
Michael S. Cuffe EVP and Chief Clinical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,330
+6.79%
|
-
|
|
Feb 13
2025
|
Jon M Foster EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
684
-2.36%
|
$219,564
$321.92 P/Share
|
|
Feb 13
2025
|
Jon M Foster EVP and COO |
BUY
Grant, award, or other acquisition
|
Direct |
2,750
+8.65%
|
-
|
|
Feb 13
2025
|
Jennifer Berres SVP & Chief Human Res. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
407
-1.61%
|
$130,647
$321.92 P/Share
|
|
Feb 13
2025
|
Jennifer Berres SVP & Chief Human Res. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,588
+5.89%
|
-
|
|
Feb 07
2025
|
Jennifer Berres SVP & Chief Human Res. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,747
-22.11%
|
$2,172,534
$322.05 P/Share
|
|
Feb 07
2025
|
Jennifer Berres SVP & Chief Human Res. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,780
+17.29%
|
$1,413,600
$120.11 P/Share
|
|
Feb 03
2025
|
Sammie S Mosier SVP & Chief Nurse Executive |
SELL
Payment of exercise price or tax liability
|
Direct |
41
-0.39%
|
$13,694
$334.3 P/Share
|
|
Feb 03
2025
|
Sammie S Mosier SVP & Chief Nurse Executive |
BUY
Exercise of conversion of derivative security
|
Direct |
138
+1.29%
|
-
|
|
Nov 14
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Open market or private sale
|
Direct |
1,474
-13.49%
|
$526,218
$357.99 P/Share
|
|
Nov 14
2024
|
Jon M Foster EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
20,902
-44.3%
|
$7,211,190
$345.51 P/Share
|
|
Nov 14
2024
|
Jon M Foster EVP and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
36,600
+43.69%
|
$3,696,600
$101.16 P/Share
|
|
Nov 14
2024
|
Jon M Foster EVP and COO |
BUY
Bona fide gift
|
Indirect |
19,955
+26.43%
|
-
|
|
Nov 14
2024
|
Jon M Foster EVP and COO |
SELL
Bona fide gift
|
Direct |
19,955
-34.69%
|
-
|
|
Nov 14
2024
|
Jon M Foster EVP and COO |
BUY
Other acquisition or disposition
|
Indirect |
9,502
+12.83%
|
$3,344,704
$352.74 P/Share
|
|
Nov 14
2024
|
Jon M Foster EVP and COO |
SELL
Other acquisition or disposition
|
Direct |
9,502
-23.73%
|
$3,344,704
$352.74 P/Share
|
|
Nov 14
2024
|
Erol R Akdamar Group President |
SELL
Open market or private sale
|
Direct |
2,900
-29.77%
|
$1,023,700
$353.0 P/Share
|
|
Nov 14
2024
|
Phillip G Billington SVP-Internal Audit Services |
SELL
Open market or private sale
|
Direct |
3,897
-6.89%
|
$1,363,950
$350.0 P/Share
|
|
Nov 12
2024
|
Erol R Akdamar Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
10,257
-51.29%
|
$3,589,950
$350.53 P/Share
|
|
Nov 12
2024
|
Erol R Akdamar Group President |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
$1,360,000
$68.96 P/Share
|
|
Nov 12
2024
|
Phillip G Billington SVP-Internal Audit Services |
SELL
Payment of exercise price or tax liability
|
Direct |
4,103
-6.76%
|
$1,436,050
$350.53 P/Share
|
|
Nov 12
2024
|
Phillip G Billington SVP-Internal Audit Services |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+11.64%
|
$544,000
$68.96 P/Share
|
|
Nov 11
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,236
-22.85%
|
$1,155,252
$357.99 P/Share
|
|
Nov 11
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,710
+24.96%
|
$814,830
$173.12 P/Share
|
|
Oct 30
2024
|
Patricia F Elcan > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
1,021,199
+14.38%
|
$368,652,839
$361.55 P/Share
|
|
Oct 30
2024
|
Patricia F Elcan > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,021,199
-51.82%
|
$368,652,839
$361.55 P/Share
|
|
Sep 12
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
8,358
-21.97%
|
$3,217,830
$385.42 P/Share
|
|
Sep 10
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,722
-26.51%
|
$5,296,692
$386.43 P/Share
|
|
Sep 10
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,080
+29.9%
|
$3,201,600
$145.24 P/Share
|
|
Aug 08
2024
|
Mike A Marks EVP and CFO |
BUY
Bona fide gift
|
Indirect |
2,237
+4.92%
|
-
|
|
Aug 08
2024
|
Mike A Marks EVP and CFO |
SELL
Bona fide gift
|
Direct |
2,237
-100.0%
|
-
|
|
Aug 08
2024
|
Samuel N Hazen CEO |
BUY
Bona fide gift
|
Indirect |
7,115
+32.2%
|
-
|
|
Aug 08
2024
|
Samuel N Hazen CEO |
SELL
Bona fide gift
|
Indirect |
7,115
-100.0%
|
-
|
|
Aug 06
2024
|
Samuel N Hazen CEO |
BUY
Bona fide gift
|
Indirect |
22,211
+47.31%
|
-
|
|
Aug 06
2024
|
Samuel N Hazen CEO |
SELL
Bona fide gift
|
Direct |
22,211
-9.44%
|
-
|
|
Aug 05
2024
|
Joseph A Sowell Iii SVP; Chief Development Officer |
BUY
Bona fide gift
|
Indirect |
13,367
+41.91%
|
-
|
|
Aug 05
2024
|
Joseph A Sowell Iii SVP; Chief Development Officer |
SELL
Bona fide gift
|
Direct |
13,367
-100.0%
|
-
|
|
Jul 31
2024
|
Timothy M Mc Manus Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,919
-12.67%
|
$1,422,597
$363.05 P/Share
|